10-K: Guardant Health Reports Strong Revenue Growth Amidst Expanding Product Portfolio and Key Regulatory Wins

Guardant Health, a precision oncology company, reported a 33% increase in total revenue to $982.0 million for fiscal year 2025, driven by growth across its oncology, biopharma, and newly commercialized screening segments, despite continued net losses.

Summary

• Total revenue for the year ended December 31, 2025, increased by 33% to $982.0 million, up from $739.0 million in 2024.
• Oncology revenue grew by 26% to $683.6 million in 2025, with test volume increasing to approximately 276,000 from 206,700 in 2024.
• Biopharma and data revenue increased by 18% to $210.1 million in 2025, primarily due to higher GuardantINFINITY test volume and milestone achievements from companion diagnostic development agreements.
• Screening revenue reached $79.7 million in 2025, generated from approximately 87,000 Shield screening tests, a significant increase from $5.1 million in 2024.
• Net loss for 2025 was $416.3 million, an improvement from $436.4 million in 2024 and $479.4 million in 2023.
• Cash, cash equivalents, restricted cash, and marketable debt securities totaled approximately $1.3 billion as of December 31, 2025.
• The Shield blood test received FDA approval for primary colorectal cancer screening in adults aged 45 and older and met Medicare coverage requirements in August 2024.
• Medicare expanded coverage for the Guardant Reveal test to monitor disease recurrence in colorectal cancer patients in the surveillance setting, effective January 2025.
• Medicare increased the reimbursement rate for the Guardant360 Liquid test to match the Guardant360 CDx test, effective January 1, 2024.
• The company acquired MetaSight Diagnostics Ltd. in December 2025 for $59.0 million in upfront cash, plus up to $90.0 million in contingent consideration.
• A jury verdict was entered against the company in November 2023 in a patent infringement suit by TwinStrand Biosciences and the University of Washington, awarding $83.4 million in damages, which the company is vigorously contesting and appealing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting strong revenue growth and significant strategic advancements in product development, regulatory approvals, and market penetration. However, the persistent net losses and material legal liabilities temper the overall sentiment, indicating ongoing execution risks.

Positives

• Achieved substantial revenue growth of 33% year-over-year, reaching $982.0 million in 2025.
• Significant increase in screening revenue to $79.7 million in 2025, following the successful commercial launch of the Shield blood test.
• FDA approval of the Shield blood test for primary colorectal cancer screening and its inclusion in Medicare coverage and National Comprehensive Cancer Network guidelines are major market penetration milestones.
• Expanded Medicare coverage for Guardant Reveal for recurrence monitoring and Guardant360 Tissue for DNA and RNA testing enhances market access and reimbursement.
• Net losses decreased from $436.4 million in 2024 to $416.3 million in 2025, indicating a trend towards improved financial performance.
• Strong cash position with $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities as of December 31, 2025.
• Successful follow-on public offering in November 2025 raised $327.3 million in net proceeds, strengthening capital resources.
• The Smart Platform, utilizing multiomic insights and AI, is expected to drive R&D efficiencies, faster turnaround times, and cost savings.
• International expansion efforts are progressing with partnerships in Europe (Spain, UK, Italy) and regulatory approval/reimbursement in Japan and China.

Negatives

• Continued to incur significant net losses, totaling $416.3 million in 2025, and has an accumulated deficit of $3.0 billion since inception.
• Sales and marketing expenses increased significantly by 36% to $494.7 million in 2025, outpacing revenue growth in some segments.
• Interest income decreased by 36% to $34.1 million in 2025, primarily due to reduced average investment balances and lower market rates of return.
• Incurred an impairment of $18.6 million on non-marketable equity security investments in 2025.
• A jury verdict of $83.4 million in damages was entered against the company in November 2023 for patent infringement, which remains a significant legal and financial liability, despite ongoing appeals and USPTO challenges to the patents' validity.
• The company relies on a limited number of suppliers for critical laboratory instruments and materials, posing supply chain risks if replacements are not readily available.
• Operating results may fluctuate significantly due to factors outside of control, including demand, timing of R&D, regulatory approvals, and payer policies, making future results difficult to predict.

Risks

• Incurred significant losses since inception and may continue to incur losses, potentially failing to generate sufficient revenue to achieve and maintain profitability.
• Current or future products may not achieve or maintain sufficient commercial market acceptance, impacting revenue and profitability.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing them to fall below expectations or guidance.
• New product development and commercialization involve lengthy and complex processes, with no assurance of timely development or commercialization, or even success in producing commercial products for early cancer detection.
• High dependence on sales of existing tests for revenue, and inability to achieve commercial success for these tests would materially and adversely affect the business.
• Products may not meet patient and customer expectations, leading to suffering operating results, reputation, and business.
• Inability to support demand for current and future products, including adequate capacity and managing anticipated growth, could harm the business.
• Failure to maintain or enter into new relationships with biopharmaceutical companies could reduce revenue prospects and delay product development.
• Inability to compete successfully with existing and new competitors (including larger, well-financed companies) could prevent revenue increase or sustained profitability.
• Challenges in attracting and retaining qualified personnel due to competitive labor markets could hinder effective management of future growth and execution of business strategy.
• Reliance on a limited number of sole suppliers for laboratory instruments and materials poses risks of supply chain interruption and difficulties in transitioning to alternative suppliers.
• Conducting business in a heavily regulated industry means changes in regulations or violations could reduce revenue, adversely affect operations, and harm the business.
• Future changes in FDA enforcement discretion for Laboratory Developed Tests (LDTs) could subject product offerings to more significant regulatory requirements, increasing compliance costs and delaying commercialization.
• Third-party payers (commercial and government) may not provide coverage or adequate reimbursement for tests, negatively affecting business and results of operations.
• Complex and time-consuming billing and claim processing, with delays or non-compliance potentially hindering collection and adversely affecting revenue.
• Issued patents covering products, services, or technology could be found invalid or unenforceable if challenged, leading to increased competition.
• The price of common stock has fluctuated substantially and may do so in the future, with no guarantee of reselling shares at or above purchase price.
• Indebtedness could expose the company to risks adversely affecting business, financial condition, and results of operations, or result in dilution to stockholders.
• Cybersecurity incidents such as security breaches, data loss, and other disruptions could compromise sensitive information, prevent access, and expose the company to substantial liability and reputational harm.
• Increasing usage of artificial intelligence technologies may expose the company to operational, regulatory, legal, and reputational risks, including inaccurate outputs, data security concerns, and evolving regulations.

Future Outlook

The company expects to continue incurring operating losses in the near future as it invests in clinical studies, develops new products, expands its sales organization, and increases marketing efforts. Capital expenditure requirements may increase with growing demand for tests. The company believes its current cash and anticipated cash flows will be sufficient for over 12 months, but may seek additional capital for business expansion, strategic investments, or other financing opportunities.

Management Comments

• "Our objective is to be the leading provider of therapy selection, minimal residual disease detection, and early cancer screening products for cancer management across all stages of the disease and drive commercial adoption of our products."
• "We believe our commercial success is dependent upon our ability to continue to successfully market and sell our current and future products, to continue to expand our current relationships and develop new relationships with clinicians and biopharmaceutical customers and to develop and commercialize new products."
• "We believe our Smart Platform is unlocking the power of the epigenome, broadening the understanding of what drives cancer biology while providing industry leading sensitivity at high specificity and low cost."
• "We have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation."
• "We are fully cooperating with the investigation [from the United States Attorney for the Northern District of California]. At this time, we are unable to predict the outcome of this investigation."
• "We strongly disagree with the jury verdict [in the TwinStrand Biosciences case] and will vigorously contest the verdict and judgment through post-trial motions in the District Court, and if needed, through appeal to the U.S. Court of Appeals for the Federal Circuit."

Industry Context

StockSavvy.ai notes that Guardant Health operates in the rapidly evolving precision oncology and liquid biopsy market, characterized by intense competition from established diagnostic companies like Foundation Medicine, Caris Life Sciences, Tempus AI, Exact Sciences, and Natera, as well as next-generation sequencing platform providers. The company's strategy to expand across all stages of cancer care, from screening to therapy selection and recurrence monitoring, aligns with broader industry trends focusing on early detection and personalized medicine. The increasing regulatory approvals and reimbursement coverage for liquid biopsy tests, such as Guardant Health's Shield and Guardant Reveal, indicate a growing acceptance and integration of these advanced diagnostics into standard clinical practice, which is a positive industry trend for the company. However, the industry also faces significant legal challenges related to intellectual property, as evidenced by Guardant Health's ongoing patent disputes, which are common in high-innovation sectors.

Comparison to Industry Standards

• Guardant Health's Shield blood test is the first blood test approved by the FDA for primary colorectal cancer screening, setting a new benchmark in non-invasive screening options compared to traditional methods like colonoscopy or stool-based tests offered by competitors like Exact Sciences (Cologuard).
• The Guardant360 CDx test is noted as the first comprehensive liquid biopsy test approved by the FDA, positioning it as a market leader in tumor mutation profiling and companion diagnostics, competing with tissue-based tests and other liquid biopsy offerings from companies such as Foundation Medicine and Caris Life Sciences.
• The Guardant Reveal test's expansion into late-stage therapy response monitoring and its proven performance in minimal residual disease (MRD) detection in early-stage colorectal, breast, and lung cancers places it in direct competition with Natera's Signatera assay and other MRD tests from companies like Tempus AI and Personalis.
• The company's Smart Platform, leveraging multi-modal biology with genomic, epigenomic, and RNA-based data, represents an advanced technological approach that aims to provide deeper insights compared to competitors relying solely on genomic profiling.
• The inclusion of the Shield blood test in National Comprehensive Cancer Network (NCCN) colorectal cancer screening guidelines signifies a strong endorsement by a leading oncology organization, enhancing its credibility and adoption potential compared to tests not yet included in such guidelines.

Legal Proceedings

• A jury verdict was entered against the company in November 2023 in a patent infringement suit by TwinStrand Biosciences, Inc. and the University of Washington, awarding $83.4 million in damages (6% royalty on past sales). The company is vigorously contesting and appealing this verdict. The USPTO issued an office action in January 2026 rejecting all claims of the '631 Patent as invalid, and the U.S. Court of Appeals for the Federal Circuit remanded the '127 Patent for invalidity review in January 2026.
• The company filed a patent infringement suit against Tempus AI, Inc. in June 2024, alleging infringement of five U.S. patents and seeking an injunction and compensatory damages. A trial is set for October 2028.
• Tempus AI, Inc. filed a patent infringement lawsuit against the company in March 2025, alleging infringement of four U.S. patents. The court granted the company's motion to dismiss all claims in January 2026, finding them patent-ineligible, and Tempus has indicated it will appeal.
• Cold Spring Harbor Laboratory filed a patent infringement lawsuit against the company in March 2025, alleging infringement related to Copy Number Variation (CNV) calling in Guardant360. Discovery is ongoing, with a Markman hearing in April 2026 and trial in April 2027.
• The company filed a declaratory judgment action against Natera, Inc. in May 2021, alleging false advertising and unfair competition regarding Guardant Reveal. A jury found in favor of the company in November 2024, awarding $292.5 million ($175.5 million in punitive damages). The court granted sanctions of $3.0 million in attorneys' fees and injunctive relief in July 2025, affirming a total damages award of $287.0 million.
• The company received a civil investigative demand (CID) from the United States Attorney for the Northern District of California in January 2022, in connection with an investigation under the False Claims Act regarding billing government-funded programs for Guardant360. The company is cooperating but cannot predict the outcome.
• The company is a defendant in two wage and hour class action lawsuits in California Superior Courts, alleging violations of the California Labor Code, including claims for unpaid wages, overtime, meal/rest period violations, and unlawful non-compete clauses. The company denies the allegations, and the outcome is uncertain at this early stage.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity raises, but also benefit from strong revenue growth and expanding market opportunities. Legal liabilities and ongoing losses pose risks to stock price volatility and profitability.
• **Patients**: Benefit from expanded access to advanced cancer diagnostic and screening tests (Guardant360, Guardant Reveal, Shield), potentially leading to earlier detection, more precise treatment selection, and improved outcomes.
• **Healthcare Providers (Oncologists, Primary Care Physicians)**: Gain access to a broader portfolio of liquid and tissue biopsy tests, including FDA-approved and guideline-recommended options, aiding in treatment decisions and recurrence monitoring.
• **Biopharmaceutical Companies**: Benefit from collaborations for drug development, companion diagnostics, and data services through platforms like GuardantINFORM and GuardantConnect, accelerating precision oncology research.
• **Payers (Medicare, Commercial Insurers, VA, TRICARE)**: Increased coverage and reimbursement for Guardant Health's tests, particularly Shield, indicates growing acceptance of the clinical utility and value of these diagnostics, but also implies increased costs for payers.
• **Employees**: Continued growth and investment in R&D and commercial teams create employment opportunities, but competitive labor markets pose challenges for attraction and retention. Wage and hour lawsuits indicate potential employee relations and compliance risks.

Next Steps

• Continue to increase awareness of products through screening awareness initiatives, direct-to-consumer channels, and education of biopharmaceutical companies, KOLs, and advocacy groups.
• Advocate for inclusion of tests in treatment guidelines and expand global access through direct investment and partnerships.
• Work with commercial and government payers to establish coverage and reimbursement for tests, investing in clinical and real-world evidence to expand indications for use.
• Pursue FDA and international regulatory approvals for tests to facilitate reimbursement and global market access.
• Continue to develop and seek approval of products as companion diagnostics for targeted and immuno-oncology therapies.
• Expand lab capabilities and services through partnerships.
• Continue patient enrollment for the required Shield post-FDA-approval SOLAR study into 2026, aiming to conclude by 2031.
• Continue the SHIELD LUNG study to clinically validate the next-generation Shield blood test in lung cancer screening.
• Participate in the Vanguard study funded by the National Cancer Institute to inform the design of a randomized controlled trial for multi-cancer detection tests.
• Vigorously contest the jury verdict and judgment in the TwinStrand Biosciences patent infringement suit through post-trial motions and appeal to the U.S. Court of Appeals for the Federal Circuit.
• Continue discovery in the patent infringement suit against Tempus AI, Inc., with a trial set for October 2028.
• Continue discovery in the Cold Spring Harbor Laboratory patent infringement lawsuit, with a Markman hearing scheduled for April 2, 2026, and trial in April 2027.
• Monitor the appeal by Tempus AI, Inc. following the dismissal of its patent infringement lawsuit against the company.
• Continue to defend against wage and hour class action lawsuits in California Superior Courts.

Key Dates

Recommendation

Guardant Health demonstrates robust revenue growth and significant strategic progress, particularly with the FDA approval and Medicare coverage of its Shield blood test, which are critical for long-term market penetration. The company's expanding product portfolio and international partnerships also present substantial growth opportunities. However, the company continues to incur significant net losses and faces material legal liabilities from ongoing patent infringement and false advertising lawsuits, which introduce considerable financial uncertainty. While operational improvements are evident in reduced cash burn from operations, the path to sustained profitability remains challenging in a highly competitive and evolving market. A seasoned investor would likely 'hold' the stock, acknowledging the strong operational momentum and market potential, but also recognizing the substantial risks and the need for continued execution to achieve profitability and resolve legal challenges.

Keywords

Precision Oncology, Liquid Biopsy, Cancer Screening, Genomic Profiling, FDA Approval, Medicare Coverage, Guardant360, Guardant Reveal, Shield Test, Biopharmaceutical Partnerships, Molecular Diagnostics, AI Analytics, Circulating Tumor DNA, Epigenomics, Companion Diagnostics, Minimal Residual Disease, Colorectal Cancer, Lung Cancer, Breast Cancer, Healthcare Reimbursement